These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15252704)

  • 1. Pretreatment neurophysiological and clinical characteristics of placebo responders in treatment trials for major depression.
    Leuchter AF; Morgan M; Cook IA; Dunkin J; Abrams M; Witte E
    Psychopharmacology (Berl); 2004 Dec; 177(1-2):15-22. PubMed ID: 15252704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in brain function of depressed subjects during treatment with placebo.
    Leuchter AF; Cook IA; Witte EA; Morgan M; Abrams M
    Am J Psychiatry; 2002 Jan; 159(1):122-9. PubMed ID: 11772700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression.
    Hunter AM; Leuchter AF; Morgan ML; Cook IA
    Am J Psychiatry; 2006 Aug; 163(8):1426-32. PubMed ID: 16877657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does prior antidepressant treatment of major depression impact brain function during current treatment?
    Hunter AM; Cook IA; Leuchter AF
    Eur Neuropsychopharmacol; 2012 Oct; 22(10):711-20. PubMed ID: 22445212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorder.
    Hunter AM; Muthén BO; Cook IA; Leuchter AF
    J Psychiatr Res; 2010 Jan; 44(2):90-8. PubMed ID: 19631948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain functional changes (QEEG cordance) and worsening suicidal ideation and mood symptoms during antidepressant treatment.
    Hunter AM; Leuchter AF; Cook IA; Abrams M
    Acta Psychiatr Scand; 2010 Dec; 122(6):461-9. PubMed ID: 20384600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QEEG Theta Cordance in the Prediction of Treatment Outcome to Prefrontal Repetitive Transcranial Magnetic Stimulation or Venlafaxine ER in Patients With Major Depressive Disorder.
    Bares M; Brunovsky M; Novak T; Kopecek M; Stopkova P; Sos P; Höschl C
    Clin EEG Neurosci; 2015 Apr; 46(2):73-80. PubMed ID: 24711613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
    Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
    J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurophysiologic predictors of treatment response to fluoxetine in major depression.
    Cook IA; Leuchter AF; Witte E; Abrams M; Uijtdehaage SH; Stubbeman W; Rosenberg-Thompson S; Anderson-Hanley C; Dunkin JJ
    Psychiatry Res; 1999 Mar; 85(3):263-73. PubMed ID: 10333379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
    Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
    J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning.
    Trivedi MH; Corey-Lisle PK; Guo Z; Lennox RD; Pikalov A; Kim E
    Int Clin Psychopharmacol; 2009 May; 24(3):133-8. PubMed ID: 19318972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early changes in prefrontal activity characterize clinical responders to antidepressants.
    Cook IA; Leuchter AF; Morgan M; Witte E; Stubbeman WF; Abrams M; Rosenberg S; Uijtdehaage SH
    Neuropsychopharmacology; 2002 Jul; 27(1):120-31. PubMed ID: 12062912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
    Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D
    Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies.
    Weisler RH; Montgomery SA; Earley WR; Szamosi J; Lazarus A
    Int Clin Psychopharmacol; 2012 Jan; 27(1):27-39. PubMed ID: 22027845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Site versus centralized raters in a clinical depression trial: impact on patient selection and placebo response.
    Kobak KA; Leuchter A; DeBrota D; Engelhardt N; Williams JB; Cook IA; Leon AC; Alpert J
    J Clin Psychopharmacol; 2010 Apr; 30(2):193-7. PubMed ID: 20520295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting placebo response in adolescents with major depressive disorder: The Adolescent Placebo Impact Composite Score (APICS).
    Nakonezny PA; Mayes TL; Byerly MJ; Emslie GJ
    J Psychiatr Res; 2015 Sep; 68():346-53. PubMed ID: 26028546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurophysiologic predictors of response to atomoxetine in young adults with attention deficit hyperactivity disorder: a pilot project.
    Leuchter AF; McGough JJ; Korb AS; Hunter AM; Glaser PE; Deldar A; Durell TM; Cook IA
    J Psychiatr Res; 2014 Jul; 54():11-8. PubMed ID: 24726639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.